Brand-name drug · amylin analog
Symlin (pramlintide)
From the FDA label, read Published by PepVault
Symlin is pramlintide from AstraZeneca, a lab-made version of amylin, a hormone the pancreas releases together with insulin after a meal; it is injected from a pen right before each main meal.
FDA approved it as an add-on for people with type 1 or type 2 diabetes who use mealtime insulin and have not reached their blood sugar goal despite the best insulin treatment.
Symlin is being withdrawn: Drugs@FDA lists every Symlin product as discontinued, and the product data on its label gives January 31, 2027 as the end of marketing for both SymlinPen 60 and SymlinPen 120.
- Active ingredient
- Pramlintide
- Maker
- AstraZeneca
- Class
- amylin analog
- FDA application
- NDA 021332, first approved 2005
What FDA approved it for
The label is strict about who it suits: people under the care of an insulin expert with diabetes educators behind them. It rules out an HbA1c above 9%, severe low blood sugar needing help in the past 6 months, not feeling low blood sugar coming on, a slow-emptying stomach (gastroparesis) and children.
From the label: 12.1 Mechanism of Action; 1 Indications and Usage; 5.1 Patient Selection; Product data (SPL).
How it is supplied
| Form | Doses |
|---|---|
| SymlinPen 60 | 15 mcg, 30 mcg, 45 mcg, 60 mcg |
| SymlinPen 120 | 60 mcg, 120 mcg |
From the label: 3 Dosage Forms and Strengths.
The label’s dosing schedule
This is the dosing schedule as the FDA label states it. A prescriber sets the actual dose and when it changes; it is not an instruction to the reader.
Type 2 diabetes, before each main meal
| Dose | When, on the label |
|---|---|
| 60 mcg before each main meal | To start, with the mealtime insulin cut by half |
| 120 mcg before each main meal | Once there has been no significant nausea for at least 3 days |
If nausea keeps up at 120 mcg, the label goes back down to 60 mcg.
Type 1 diabetes, before each main meal
| Dose | When, on the label |
|---|---|
| 15 mcg before each main meal | To start, with the mealtime insulin cut by half |
| 30 mcg before each main meal | After at least 3 days without significant nausea |
| 45 mcg before each main meal | After at least 3 more days without significant nausea |
| 60 mcg before each main meal | The top step, reached the same way |
If nausea persists at 45 or 60 mcg, the label steps back to 30 mcg, and if 30 mcg is not tolerated, stopping Symlin is considered.
Each rise waits at least 3 days, to keep nausea down, and blood sugar is checked often, before and after meals and at bedtime, while the dose is set.
From the label: 2.2 Patients with Type 2 Diabetes Using Mealtime Insulin; 2.3 Patients with Type 1 Diabetes; 2.1 Important Considerations Pertaining to SYMLIN and Insulin Dose Adjustments.
How it’s taken
Each dose goes under the skin of the belly or thigh, not the arm, right before a main meal, meaning one of at least 250 calories or 30 grams of carbohydrate. The spot should be away from where the insulin goes.
Symlin and insulin are always two separate shots and are never mixed in one syringe. When Symlin starts, the mealtime insulin dose is cut by half to lower the chance of a low.
Because Symlin slows how fast the stomach empties, a pill whose quick effect matters (a pain reliever, for example) is taken at least 1 hour before the shot or 2 hours after it.
From the label: 2.4 Administration; 2.1 Important Considerations Pertaining to SYMLIN and Insulin Dose Adjustments; 5.5 Concomitantly Administered Oral Medications.

If a dose is missed
A missed Symlin dose is not made up: the usual dose is taken before the next main meal.
From the label: 2.4 Administration.
Storage
Pens not yet in use are kept in the fridge at 36°F to 46°F, out of light, and never frozen. Once in use, a pen can stay in the fridge or at up to 86°F, and is used within 30 days.
From the label: 16 How Supplied/Storage and Handling.
Side effects and warnings
| Reaction | Placebo | 30 or 60 mcg |
|---|---|---|
| Nausea | 17 | 48 |
| Loss of appetite (anorexia) | 2 | 17 |
| Injuries | 10 | 14 |
| Vomiting | 7 | 11 |
| Joint pain (arthralgia) | 5 | 7 |
| Tiredness | 4 | 7 |
| Allergic reaction | 5 | 6 |
| Dizziness | 4 | 5 |
Nausea came in 48% of people with type 1 diabetes against 17% on placebo, and in 28% against 12% in type 2 diabetes on 120 mcg. The label says nausea is highest at the start and fades with time for most people, and that the slow climb keeps it down.
The boxed warning
The other warnings
Its other warnings: a Symlin pen is never shared, even with a new needle; Symlin and insulin are never mixed; it can delay pills taken alongside it; it is not used with medicines that speed up the gut; and it can cause allergic reactions. On its own, without insulin, Symlin does not cause low blood sugar.
From the label: 6.1 Clinical Trial Experience; Boxed Warning; 5 Warnings and Precautions.
What else we have on pramlintide
Pramlintide on PepVault
Free tools
The trials, in plain English
Compound against compound
Questions about Symlin
Is Symlin discontinued?
Drugs@FDA lists every Symlin product as discontinued, and its label’s product data gives January 31, 2027 as the end of marketing for both SymlinPen 60 and SymlinPen 120.
What is the dose of Symlin?
In type 2 diabetes the label starts at 60 mcg before each main meal and moves to 120 mcg; in type 1 it starts at 15 mcg and rises in 15 mcg steps to 30, 45 or 60 mcg. A prescriber sets the dose and the insulin change that goes with it.
Why is the insulin dose lowered when Symlin starts?
Symlin with insulin raises the risk of severe low blood sugar, so the label cuts the mealtime insulin by half at the start.
What if a Symlin dose is missed?
It is not made up; the usual dose is taken before the next main meal.
What is the most common side effect of Symlin?
Nausea: 48% in the type 1 trials against 17% on placebo, and 28% against 12% in type 2 on 120 mcg. It is usually worst at the start.
Sources
- SYMLIN (pramlintide acetate) injection for subcutaneous use, FDA label on DailyMed (version 18, published Aug 20, 2024; read Nov 18, 2026)
- Drugs@FDA, NDA 021332 (Symlin, SymlinPen 60 and SymlinPen 120; application first approved 2005)
PepVault is not affiliated with AstraZeneca. Symlin is a trademark of its owner.